Subtitle
Long-term outcome of a prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.
Subtitle
Long-term outcome of a prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.
Proto therapy Time
January 2017
Executive summary
This MD Anderson study published in the Green Journal reported proton therapy for early stage NSCLC patients who were not suitable for SBRT due to lesion size and location. The study reported encouraging 5-year overall survival rate and recurrence-free rate.
The authors concluded that this long-term follow-up data demonstrated proton therapy with ablative doses is well tolerated and effective in medically inoperable early-stage NSCLC
Top cancer treatments
Related contents
Proton Therapy Publication
June 2024
Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry.
Proton Therapy Publication
July 2024
A Pilot Trial of Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable Non-Small Cell Lung Cancer with Extended Durvalumab Therapy (PARTICLE-D).
Proton Therapy Publication
August 2024
Sparing of the heart facilitates recovery from cardiopulmonary side effects after thoracic irradiation.
Proton Therapy Publication
August 2024
Parallel explorations in LA-NSCLC: Chemoradiation dose-response optimisation considering immunotherapy and cardiac toxicity sparing.
Proton Therapy Publication
April 2024
A bibliometric analysis of cardiotoxicity in cancer radiotherapy.
Proton Therapy Publication
March 2024
FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): protocol for a prospective study of a novel radiotherapy approach.
Proton Therapy Publication
February 2024
Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer.
Proton Therapy Publication
April 2024
Long-term survival outcomes and quality of life of image-guided proton therapy for operable stage I non-small cell lung cancer: A phase 2 study.
Proton Therapy Publication
January 2024
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.